01—Abstract
Summary
Summary of the 10-Q filed October 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. reported strong financial results for the nine months ended September 26, 2026, demonstrating robust revenue growth and improved profitability.
Total revenues increased by 9% year-over-year, reaching $35.14 billiona, driven by broad-based strength across its segments, particularly Laboratory Products and Biopharma Services and Life Sciences Solutions. The company's operational efficiency and strategic acquisitions contributed significantly to its performance. Adjusted operating income grew by 12% to $8.10 billion, with adjusted operating income margin expanding to 23.1%.
This growth reflects strong productivity improvements and successful integration of recent acquisitions, notably Clario Holdings, Inc. Financially, Thermo Fisher maintained a solid balance sheet, though total debt increased to $41.37 billionb. The company generated substantial operating cash flow of $5.87 billion and free cash flow of $4.62 billion, underscoring its ability to fund operations, investments, and shareholder returns. The company also repurchased $4.00 billion in common stock and paid $0.51 billion in dividends, indicating a commitment to returning value to shareholders.
02—Key points
Key Highlights
- Total revenues for the nine months ended September 26, 2026, increased by 9% to $35.14 billion compared to the prior year period.
- Adjusted operating income grew by 12% to $8.10 billion, with an improved adjusted operating income margin of 23.1%.
- Significant acquisition activity, including the purchase of Clario Holdings, Inc., contributed 4% to revenue growth for the nine-month period.
- The Laboratory Products and Biopharma Services segment was a key revenue driver, showing 11% organic growth for the nine months.
- Operating cash flow for the nine months was $5.87 billion, and free cash flow was $4.62 billion, demonstrating strong cash generation.
- The company repurchased $4.00 billion of its common stock and paid $0.51 billion in dividends during the nine months ended September 26, 2026.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed October 30, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $12.14B$11.12B | +9.1% |
| R&D Expenses | $348.00M$346.00M | +0.6% |
| SG&A Expenses | $2.32B$2.16B | +7.4% |
| Operating Expenses | $9.87B$9.18B | +7.5% |
| Operating Income | $2.26B$1.94B | +16.6% |
| Net Income | $1.73B$1.62B | +6.5% |
| EPS (Basic) | $4.65$4.28 | +8.6% |
| EPS (Diluted) | $4.64$4.27 | +8.7% |
| Shares Outstanding (Basic) | 370.00M378.00M | −2.1% |
| Shares Outstanding (Diluted) | 371.00M378.00M | −1.9% |
05—Questions
Frequently Asked Questions
How did Thermo Fisher Scientific's revenue perform in the reported period?
Thermo Fisher Scientific reported a 9% increase in total revenues for the nine months ended September 26, 2026, reaching $35.14 billion. This growth was driven by organic factors and contributions from acquisitions.
What is the company's profitability trend?
Profitability improved, with adjusted operating income increasing by 12% to $8.10 billion for the nine months ended September 26, 2026. The adjusted operating income margin also expanded to 23.1%.
What is the company's approach to capital allocation?
Thermo Fisher Scientific continues to deploy capital through strategic acquisitions, share repurchases, and dividend payments. During the nine months ended September 26, 2026, the company repurchased $4.00 billion of common stock and paid $0.51 billion in dividends.
How has the company managed its debt levels?
Total debt increased to $41.37 billion as of September 26, 2026. The company indicated that its existing cash, cash flow from operations, and available borrowing capacity are expected to be sufficient to meet its cash requirements.
06—Continue